Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone

Journal of Bone and Mineral Research

Volumn 27, Issue 2, 2012, Pages 461-473

  Harada, Suguru ^a,b   Mizoguchi, Toshihide ^a   Kobayashi, Yasuhiro ^a   Nakamichi, Yuko ^a   Takeda, Satoshi ^b   Sakai, Sadaoki ^b   Takahashi, Fumiaki ^b   Saito, Hitoshi ^b   Yasuda, Hisataka ^c   Udagawa, Nobuyuki ^a   Suda, Tatsuo ^d   Takahashi, Naoyuki ^a  

^a MATSUMOTO DENTAL UNIVERSITY   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c Oriental Yeast Co Ltd   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

ACTIVE VITAMIN D; BONE METABOLISM; ELDECALCITOL; OSTEOCLAST; RANKL

Indexed keywords

ELDECALCITOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MARROW CELL; BONE METABOLISM; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; EX VIVO STUDY; FEMUR; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; METAPHYSIS; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; TRABECULAR BONE;

EID: 84856200641     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.555     Document Type: Article

References (55)

1. Martin TJ, Sims NA,. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005; 11: 76-81. (Pubitemid 40193486)
2. Riggs BL, Khosla S, Melton LJ 3rd., A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998; 13: 763-73. (Pubitemid 28224192)
3. Seeman E,. Pathogenesis of bone fragility in women and men. Lancet. 2002; 359: 1841-50. (Pubitemid 34607063)
4. Chambers TJ,. Regulation of the differentiation and function of osteoclasts. J Pathol. 2000; 192: 4-13.
5. Martin TJ, Romas E, Gillespie MT,. Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr. 1998; 8: 107-23. (Pubitemid 30152112)
6. Roodman GD,. Cell biology of the osteoclast. Exp Hematol. 1999; 27: 1229-41. (Pubitemid 29347472)
7. Arron JR, Choi Y,. Bone versus immune system. Nature. 2000; 408: 535-6.
8. Boyle WJ, Simonet WS, Lacey DL,. Osteoclast differentiation and activation. Nature. 2003; 423: 337-42. (Pubitemid 40852708)
9. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL,. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res. 2000; 15: 2-12. (Pubitemid 30026926)
10. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ,. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20: 345-57. (Pubitemid 30649812)
11. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T,. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000; 141: 1554-9. (Pubitemid 32269125)
12. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ,. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309-19. (Pubitemid 27199902)
13. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, Shinki T, Gillespie MT, Martin TJ, Higashio K, Suda T,. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000; 141: 3478-84. (Pubitemid 32269038)
14. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K,. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998; 139: 1329-37. (Pubitemid 28510154)
15. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ,. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165-76. (Pubitemid 28180851)
16. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T,. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95: 3597-602.
17. Mizoguchi T, Muto A, Udagawa N, Arai A, Yamashita T, Hosoya A, Ninomiya T, Nakamura H, Yamamoto Y, Kinugawa S, Nakamura M, Nakamichi Y, Kobayashi Y, Nagasawa S, Oda K, Tanaka H, Tagaya M, Penninger JM, Ito M, Takahashi N,. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol. 2009; 184: 541-54.
18. Bouillon R, Okamura WH, Norman AW,. Structure-function relationships in the vitamin D endocrine system. Endocrine Rev. 1995; 16: 200-57.
19. 3-1α-hydroxylase gene promoter. Proc Natl Acad Sci USA. 1998; 95: 1387-91.
20. 3. Biochem Biophys Res Commun. 1998; 249: 11-6. (Pubitemid 28418685)
21. 3 in intact animals. Endocrinology. 1999; 140: 2224-31. (Pubitemid 30636463)
22. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T,. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8. (Pubitemid 38542505)
23. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW,. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res. 1998; 13: 325-49. (Pubitemid 28146215)
24. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S,. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet. 1997; 16: 391-6. (Pubitemid 27323308)
25. Malloy PJ, Pike JW, Feldman D,. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev. 1999; 20: 156-88. (Pubitemid 29341671)
26. Yagishita N, Yamamoto Y, Yoshizawa T, Sekine K, Uematsu Y, Murayama H, Nagai Y, Krezel W, Chambon P, Matsumoto T, Kato S,. Aberrant growth plate development in VDR/RXR Î double null mutant mice. Endocrinology. 2001; 142: 5332-41. (Pubitemid 33131966)
27. Suda T, Ueno Y, Fujii K, Shinki T,. Vitamin D and bone. J Cell Biochem. 2003; 88: 259-66. (Pubitemid 36119896)
28. Suda T,. Vitamin D and bone: how does vitamin D regulate bone formation and resorption?. Proc Jpn Acad Ser B. 2004; 80: 407-21.
29. Yasuda H, Higashio K, Suda T,. Vitamin D and osteoclastogenesis. In:, Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. Burlington, MA: Elsevier Academic Press; 2005. p. 665-86.
30. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY,., Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int. 2005; 76: 176-86. (Pubitemid 41557146)
31. 3 with an oxygen atom in their side chain. Biochem Int. 1989; 19: 1143-9. (Pubitemid 19281097)
32. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int. 1994; 54: 142-9. (Pubitemid 24046725)
33. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y,. Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res. 1996; 11: 325-36. (Pubitemid 26076382)
34. Uchiyama Y, Higuch IY, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, Ogata E,. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 2002; 30: 582-8. (Pubitemid 34270495)
35. 3, increases bone mineral density regardless of serum 25(OH)D levels in osteoporotic subjects. J Steroid Biochem Mol Biol. 2007; 103: 584-6. (Pubitemid 46401355)
36. 3 derivative, on calcium metabolism. Biochem Biophys Res Commun. 1989; 163: 1444-9. (Pubitemid 19244750)
37. 3 analogues bearing a hydroxyalkoxy group at the 2β-position. Chem Pharm Bull (Tokyo). 1993; 41: 1111-3. (Pubitemid 23240095)
38. 3 (ED-71). J Steroid Biochem Mol Biol. 2007; 103: 222-6. (Pubitemid 46401295)
39. Harada S, Takeda S, Uno A, Takahashi F, Saito H,. Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J Steroid Biochem Mol Biol. 2010; 121: 281-3.
40. 3 in perfused rat liver. Biochem Biophys Res Commun. 1975; 66: 632-8.
41. Kawamoto T, Shimizu M,. A method for preparing 2- to 50-micron-thick fresh-frozen sections of large samples and undecalcified hard tissues. Histochem Cell Biol. 2000; 113: 331-9. (Pubitemid 30341300)
42. Kikuchi W, Namatame Y, Matsuki Y, Kiyokawa I, Nomura F, Oda K, Miura T,. Usability of serum tartrate-resistant acid phosphatase type 5b (TRACP-5b) in rat ovariectomy model. J Bone Miner Res. 2011; 26: SU0325.
43. de Freitas PH, Hasegawa T, Takeda S, Sasaki M, Tabata C, Oda K, Li M, Saito H, Amizuka N,. Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone. 2011; 49: 335-42.
44. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F,. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16: 1575-82. (Pubitemid 32786425)
45. Eriksen EF, Eghbali-Fatourechi GZ, Khosla S,. Remodeling and vascular spaces in bone. J Bone Miner Res. 2007; 22: 1-6. (Pubitemid 46032591)
46. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC,. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res. 2003; 18: 1088-98. (Pubitemid 37294947)
47. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H,. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231-4.
48. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, O'Brien CA,. Matrix-embedded cells control osteoclast formation. Nat Med. 2011; 17: 1235-41.
49. Riggs BL, Khosla S, Melton LJ 3rd., Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002; 23: 279-302. (Pubitemid 34651948)
50. Giner M, Montoya MJ, Vazquez MA, Rios MJ, Moruno R, Miranda MJ, Perez-Cano R,. Modifying RANKL/OPG mRNA expression in differentiating and growing human primary osteoblasts. Horm Metab Res. 2008; 40: 869-74.
51. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T,. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004; 20: 707-18. (Pubitemid 38757441)
52. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ, Boyde A, Suda T,. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology. 1988; 122: 1373-82. (Pubitemid 18091966)
53. Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K,. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest. 2006; 116: 528-35. (Pubitemid 43228371)
54. 3 inhibits osteoclastogenesis through IFN-β-dependent NFATc1 suppression. J Bone Miner Metab. 2009; 27: 643-52.
55. 3 analog, eldecalcitol, prevents the risk of osteoporotic fractures: a randomized, active comparator, double-blind study. Bone. 2011; 49: 605-12.